SBIO250117C36000
- 0.00
- 0.000.00%
Alps Etf Trust Medical Breakthroughs Etf Newsroom
HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Axsome Therapeutics Analyst Ratings
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Axsome Completes Phase 3 Trials for AXS-05 in Alzheimer's Agitation, Plans FDA Submission for Alzheimer's Agitation Drug in 2025
Mizuho CEO Sees Global Boom in M&A After Trump Takes Office
Rhythm Gets FDA Approval for Imcivree for Toddlers
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Hythm Pharmaceuticals Secures FDA Approval For Expanded Use Of IMCIVREE To Treat Obesity In Children As Young As 2 With Bardet-Biedl Syndrome Or MC4R Pathway Deficiencies, Targeting Rare Neuroendocrine Diseases
Five Reasons Why UBS Is Overweight the UK
J.P. Morgan's Top Healthcare Stocks for 2025
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
What 8 Analyst Ratings Have To Say About Avidity Biosciences
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals
PepGen Stock Craters 35% on FDA Clinical Hold
Crinetics Pharmaceuticals Analyst Ratings
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target